Meininger 2009.

Methods	Randomized, double‐blind, placebo‐controlled
Participants	Six countries in Europe N = 366 (glatiramer acetate: 184, placebo: 182) Mean age 55.7 years (glatiramer acetate), 56.7 years (placebo) Gender distribution, male (%): 62.5% (glatiramer acetate), 60.4% (placebo) Family history of ALS not reported in published manuscript
Interventions	Glatiramer acetate 40 mg subcutaneously x 52 weeks
Outcomes	Primary: slope of the ALSFRS‐R Secondary: time to death, tracheostomy or permanent assisted ventilation
Notes	Funded by Teva Pharmaceutical Industries